17 million deaths globally each year, with atherosclerosis as the underlying cause of most CVDs. Herein we describe the synthesis and in vitro mechanistic evaluation of novel N'-benzylidene-carbohydrazide-1H-pyrazolo[3,4-b]pyridines (3-22) designed as non-anionic antiplatelet agents and presenting a 30-fold increase in potency compared to aspirin. The mechanism underlying their antiplatelet activity
                                    心血管疾病(CVD)每年在全球造成超过1700万例死亡,其中动脉粥样硬化是大多数CVD的根本原因。在这里,我们描述了新型N'-亚苄基-碳酰
肼-1H-
吡唑并[3,4-b]
吡啶(3-22)的合成和体外机理评价,这些化合物设计为非阴离子型抗血小板药,并且在体内的作用增加了30倍与
阿司匹林相比药效强。通过一系列体外测定(包括光透射聚集法,凝块缩回和定量ELI
SA)消除了潜在的靶标,阐明了其抗血小板活性的机制,进一步确定了血栓烷B2的
生物合成减少是其主要作用机理。化合物的固有荧光使它们与血小板膜的结合易于监测。